Arctic Bioscience AS (DE:9TD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Arctic Bioscience AS reported mixed results in their HeROPA phase 2b clinical study for the treatment of mild-to-moderate psoriasis, with their drug HRO350 showing promise but not reaching the primary endpoint due to a high placebo effect. The company remains confident in the drug’s potential and is continuing the study for a full year to understand the impact of disease fluctuations. Arctic Bioscience is also working on expanding its nutraceutical pipeline and securing a sustainable financial platform while awaiting more detailed data from the ongoing study.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.
